Literature DB >> 8929203

Lymphedema initiated by aircraft flights.

J R Casley-Smith1, J R Casley-Smith1.   

Abstract

INTRODUCTION: This study arose because a number of patients volunteered that flying had triggered, or worsened, their lymphedema. The nature of lymphedema is discussed, including the pre-lymphedematous latent-phase. In this phase the limb is clinically normal, but lymphostatic. There are many of the alterations found in clinical lymphedema involving blood vessels, tissues, lymphatics, and proteolytic cells. Since edema itself impairs many of the safety factors against edema (increased tissue hydrostatic pressure, dilution of proteins in tissue fluid, increased lymphatic transport, and increased proteolysis), any edema occurring in such a limb is likely to persist as chronic lymphedema. METHOD &
RESULTS: Questionnaires were sent to 1,020 patients with lymphedema; 749 replied, with 531 answering a question about what triggered the condition. It was present from near birth in 41, but developed later in 490 (163 post-mastectomy lymphedemas, and 136 primary and 191 secondary leg lymphedemas). In 27 of the 490, it started during an aircraft flight (15 legs and 12 arms). In addition, flying caused existing lymphedema to permanently worsen in 23 arms and 44 legs in the 749 respondents. Some typical case histories are given.
CONCLUSIONS: Because of its frequency in arms and legs, it is highly likely that this triggering, or worsening, of lymphedema is produced by lowered cabin pressure. Obstruction of veins and lymphatics, and reduced muscle pumping, may contribute to this in the legs. Using additional compression for existing lymphedema, or limbs at risk, would prevent this. If it occurs, it should be treated by additional compression, using inflated splints or pressure bandages.

Entities:  

Mesh:

Year:  1996        PMID: 8929203

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  7 in total

1.  How do recovery advice and behavioural characteristics influence upper-body function and quality of life among women 6 months after breast cancer diagnosis?

Authors:  Tracey Round; Sandra C Hayes; Beth Newman
Journal:  Support Care Cancer       Date:  2005-07-13       Impact factor: 3.603

Review 2.  Preventative measures for lymphedema: separating fact from fiction.

Authors:  Yeliz Cemal; Andrea Pusic; Babak J Mehrara
Journal:  J Am Coll Surg       Date:  2011-07-28       Impact factor: 6.113

3.  Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema.

Authors:  S R Harris; M R Hugi; I A Olivotto; M Levine
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

4.  Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer.

Authors:  Chantal M Ferguson; Meyha N Swaroop; Nora Horick; Melissa N Skolny; Cynthia L Miller; Lauren S Jammallo; Cheryl Brunelle; Jean A O'Toole; Laura Salama; Michelle C Specht; Alphonse G Taghian
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

5.  Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.

Authors:  Maria S Asdourian; Meyha N Swaroop; Hoda E Sayegh; Cheryl L Brunelle; Amir I Mina; Hui Zheng; Melissa N Skolny; Alphonse G Taghian
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

Review 6.  Traveling With Cancer: A Guide for Oncologists in the Modern World.

Authors:  Sharon Heng; Brett Hughes; Michael Hibbert; Mustafa Khasraw; Zarnie Lwin
Journal:  J Glob Oncol       Date:  2019-07

7.  Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.

Authors:  Louise A Koelmeyer; Katrina Gaitatzis; Mary S Dietrich; Chirag S Shah; John Boyages; Sarah A McLaughlin; Bret Taback; Deonni P Stolldorf; Elisabeth Elder; T Michael Hughes; James R French; Nicholas Ngui; Jeremy M Hsu; Andrew Moore; Sheila H Ridner
Journal:  Cancer       Date:  2022-07-07       Impact factor: 6.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.